The cytokine model of schizophrenia: emerging therapeutic strategies
about
Acetylsalicylic acid (aspirin) for schizophreniaMethodological Issues in Cytokine Measurement in SchizophreniaFrom Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids MetabolismEffects of the modified electric convulsive treatment (MECT) on cell factors of schizophreniaUniting the neuro developmental and immunological hypotheses: Neuregulin 1 receptor ErbB and Toll-like receptor activation in first-episode schizophrenia.Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at AdulthoodThe serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosisIFNGR2 genetic polymorphism associated with sex-specific paranoid schizophrenia risk.In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma.Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients.Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disordersThe Major Histocompatibility Complex (MHC) in Schizophrenia: A Review.Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia.The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Neuroscience-informed computer-assisted cognitive training in schizophrenia.Weaving a Net of Neurobiological Mechanisms in Schizophrenia and Unraveling the Underlying Pathophysiology.Inflammatory processes and schizophrenia: two independent lines of evidence from a study of twins discordant and concordant for schizophrenic disorders.Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis.Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia.Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies.Immuno-psychiatry: an agenda for clinical practice and innovative research.Markers of inflammation in schizophrenia: association vs. causationCharacterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885.Anti-inflammatory strategies in the treatment of schizophrenia.Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo modelCytokine Serum Levels as Potential Biological Markers for the Psychopathology in Schizophrenia
P2860
Q24186077-DCB97D46-03B7-43F0-B3C6-190A9C1B69DEQ26751839-9B5F2B5F-E413-48CC-8B3D-6C16CDCC32CEQ28067617-35F67087-F4E3-4DE8-9DDD-2602723CD4E9Q33598482-0B6616FF-B674-4496-B10E-9DBF454BC331Q33829827-97931908-1C01-4057-B613-6F7B67200C44Q35565011-AFCF97A6-3B28-4F1D-B222-B95631F404CFQ35673126-BF0AB22A-0C97-4CD5-943D-8E184346CA95Q35955612-FA74BED3-0EE2-4C2D-963E-5829C01DF640Q36114055-A5955A8D-AA52-4050-9651-D4565BFFEBB1Q36915357-E56F9511-922B-47EB-BDA4-49ECA08722B3Q37083097-584917F2-86FF-488F-BC93-D649A375FD52Q37114691-B447A699-D620-4231-88F6-CAA1F9F19586Q37626366-D61CFF62-0F98-449A-89FC-26B8F7BEDEB3Q38245624-BD55FB0B-2780-4054-91AB-CE96008CE1C3Q38636092-9D77CD01-13C7-4324-92CB-A91FD5E7F342Q38718345-E545F5DD-1B2D-4578-8FE7-1C526F28C750Q38816611-AF14D6D8-0148-442A-A203-8FE674F970A7Q38817438-5596580D-BC78-45CF-AE84-19E9980B6497Q38854101-43BDB289-5D19-4410-A45B-A116FF16A41AQ39346412-9EF44227-F2CE-4792-8049-F78B89CA35B2Q41495551-718D61D5-B361-4CDE-8A1B-1B37DB2E7E94Q41656861-F7DA14D5-4241-41A8-B0A3-12F6A6F7EA73Q42378870-7483AD33-F269-4FED-8C0D-147441B4ED70Q42738765-F7335FBA-C4FF-44A0-BEA9-FB2765D921D9Q50052167-52EA7714-EFF3-4A0C-A248-D245DE5E432AQ50561727-55AFE9E3-8726-48E1-9151-E357FBEC3EADQ57697189-4E284146-C2F1-49C1-8F47-95235F3FAAE9Q59049611-A2BD2378-6AC1-460C-A247-F0001F2A937E
P2860
The cytokine model of schizophrenia: emerging therapeutic strategies
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
The cytokine model of schizophrenia: emerging therapeutic strategies
@ast
The cytokine model of schizophrenia: emerging therapeutic strategies
@en
The cytokine model of schizophrenia: emerging therapeutic strategies
@nl
type
label
The cytokine model of schizophrenia: emerging therapeutic strategies
@ast
The cytokine model of schizophrenia: emerging therapeutic strategies
@en
The cytokine model of schizophrenia: emerging therapeutic strategies
@nl
prefLabel
The cytokine model of schizophrenia: emerging therapeutic strategies
@ast
The cytokine model of schizophrenia: emerging therapeutic strategies
@en
The cytokine model of schizophrenia: emerging therapeutic strategies
@nl
P2093
P2860
P3181
P1476
The cytokine model of schizophrenia: emerging therapeutic strategies
@en
P2093
Alan S Brown
Ragy R Girgis
Samhita S Kumar
P2860
P304
P3181
P356
10.1016/J.BIOPSYCH.2013.12.002
P407
P577
2013-12-11T00:00:00Z